GlassScriptPhysician profile
Ann M Wexler
NPI 1669482576
$65,523.27
in general payments reported to CMS, 2019-2025
93 companies · $6,706 in 2025
The $6,706 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,070 · 2020: $14K · 2021: $19K · 2022: $10K · 2023: $5,766 · 2024: $7,147 · 2025: $6,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $3,290 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,971.60 |
| Consulting Fee | $3,290.00 |
| Education | $357.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32,064.74 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $3,895.81 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Adc Therapeutics America, INC. | $2,154.26 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,799.86 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Incyte Corporation | $1,754.24 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $1,659.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,351.24 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,209.08 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Novartis Pharmaceuticals Corporation | $1,172.48 | 2019-2025 | |
| Eisai INC. | $1,057.29 | 2020-2025 | |
| Daiichi Sankyo INC. | $902.90 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $895.37 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $890.71 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $838.94 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $834.34 | 2020-2025 | Zejula, Jemperli, Ojjaara |
Show all 93 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Wexler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.